| Target Price | $43.35 |
| Price | $26.73 |
| Potential |
62.18%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Beam Therapeutics Inc 2026 .
The average Beam Therapeutics Inc target price is $43.35.
This is
62.18%
register free of charge
$84.00
214.25%
register free of charge
$20.20
24.43%
register free of charge
|
|
| A rating was issued by 21 analysts: 18 Analysts recommend Beam Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2026 of
62.18%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 63.52 | 42.90 |
| 83.18% | 32.46% | |
| EBITDA Margin | -619.71% | -1,084.32% |
| 1,395.95% | 74.97% | |
| Net Margin | -593.10% | -1,038.60% |
| 1,590.35% | 75.11% |
16 Analysts have issued a sales forecast Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2025. The average Beam Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Beam Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Beam Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.58 | -4.42 |
| 166.28% | 3.49% | |
| P/E | negative | |
| EV/Sales | 39.12 |
18 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Beam Therapeutics Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 06 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


